Transient receptor potential vanilloid 1 (TRPV1), a ligand-gated cation channel highly expressed in small-diameter sensory neurons, is activated by heat, protons, and capsaicin. The phosphorylation of TRPV1 provides a versatile regulation of intracellular calcium levels and is critical for TRPV1 function in responding to a pain stimulus. We have previously reported that cyclin-dependent kinase 5 (Cdk5) activity regulates nociceptive signaling. In this article we report that the Cdk5-mediated phosphorylation of TRPV1 at threonine-407 can modulate agonist-induced calcium influx. Inhibition of Cdk5 activity in cultured dorsal root ganglia neurons resulted in a significant reduction of TRPV1-mediated calcium influx, and this effect could be reversed by restoring Cdk5 activity. Primary nociceptor-specific Cdk5 conditional-knockout mice showed reduced TRPV1 phosphorylation, resulting in significant hypoalgesia. Thus, the present study indicates that Cdk5-mediated TRPV1 phosphorylation is important in the regulation of pain signaling.
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p35 ͉ pain I n general nociceptive (painful) neural signals originate from sensory neurons in peripheral tissues and are transmitted to second-order neurons in the spinal cord, which then convey the message to specific nuclei in the brain for perception of pain. Nociception results from the activation of molecular and cellular mechanisms in damaged tissue, sensory neurons, and the spinal cord. Many cellular pathways have been implicated in nociceptive signaling, but their precise molecular mechanisms have not been clearly defined. Abnormalities in molecular pathways underlying nociceptive processes may result in chronic pain conditions. It follows that a detailed characterization of these pathways is necessary for developing effective strategies to treat pain. Signal transduction mechanisms activated by nociceptive stimuli have not been fully characterized. Recent advances, especially the cloning and characterization of the capsaicin receptor (also known as vanilloid receptor 1), remarkably improved our understanding of signal transduction in nociceptive neurons. Transient receptor potential vanilloid 1 (TRPV1) is a member of the transient receptor potential family (1, 2) . It is a polymodal ligand-gated ion channel that is expressed in smalldiameter sensory neurons (C-fibers) and is activated by heat, protons, anandamide, and leukotrienes (3) (4) (5) (6) (7) . TRPV1-knockout mice show reduced thermal hyperalgesia after inflammation (8, 9) and reduced nociceptive responsiveness in a model of bone cancer pain (10) . TRPV1 has been connected to a broad spectrum of physiological conditions and diseases such as thermal hyperalgesia, allodynia, inf lammatory bowel disease, Crohn's disease, vulvodynia, osteoarthritis, pancreatitis, gastroesophageal reflux disease, bladder disease, cystitis, and asthma (11) . There is mounting evidence that TRPV1 is subject to multiple interacting levels of control. Phosphorylation of TRPV1 is critical for its function in response to nociceptive stimuli (12) (13) (14) . We demonstrated the expression and specific activity of cyclin-dependant kinase 5 (Cdk5)/p35 in TRPV1-positive cells of dorsal root ganglia (DRG) and trigeminal ganglia and the modulation of Cdk5 activity in response to peripheral inflammatory pain (15, 16) . We also found that p35-knockout mice, which show significantly reduced Cdk5 activity, behaviorally mimic the TRPV1 knockout pain phenotype.
Cdk5, a neuron-specific, proline-directed serine/threonine kinase is activated by two noncyclin activators, p35 and/or p39. Cdk5 phosphorylates serine and threonine immediately upstream of a proline residue. In addition to an absolute requirement for proline in the ϩ1 position, Cdk5 shows a marked preference for a basic residue in the ϩ3 position and phosphorylates the consensus sequence (S/T)PX(K/H/R) (17, 18) . Several neuronal and nonneuronal substrates are phosphorylated by Cdk5 (19) , and the list of substrates is increasing (20) . Earlier studies showed that Cdk5 knockout and p35/p39 doubleknockout mice are embryonically lethal with neuronal migration defects (21, 22) , whereas p35-knockout mice show inverted neuronal layering (23) with a concurrent attenuated response to noxious heat; conversely, mice overexpressing p35 were hyperalgesic (15) .
In the present study we analyzed TRPV1 for potential phosphorylation by Cdk5. We report that Cdk5 can directly phosphorylate TRPV1 at threonine-407 and that this in turn modulates agonist-induced calcium influx. We initially found that inhibiting Cdk5 activity resulted in attenuation of capsaicininduced calcium influx in cultured DRG neurons and that this attenuation was reversible. These observations suggested that Cdk5-mediated phosphorylation of TRPV1 is important for capsaicin-mediated calcium influx through this receptor. Because germ-line Cdk5-knockout mice are embryonically lethal and p35-knockout mice present various neuronal disorders, we generated primary nociceptor-specific Cdk5 conditionalknockout (CoKO) mice to identify the precise role of Cdk5 in primary afferent pain signaling. In the basal state, the Cdk5-CoKO mice showed significant hypoalgesia, confirming the direct role of normal Cdk5 activity in primary afferent. Collectively, our findings demonstrate a molecular mechanism for the functional regulation of TRPV1 by Cdk5 and provide further insights into the role of Cdk5 in the pain pathway.
Results

Cdk5
Phosphorylates TRPV1. First, to search for putative target sites for Cdk5 phosphorylation (S/T)PX(K/H/R) in known pain proteins, we performed a broad analysis of these proteins by using the NetPhos Version 2.0 program (BioCentrum, Lyngby, Denmark). Among other potential target proteins, we identified three putative sites in TRPV1 at threonine-108 (TPPR), threonine-407 (TPNR), and serine-612 (SPPH) (Fig. 1 A and B) . Mouse, rat, dog, and human TRPV1 protein sequences aligned by using the ClustalW program (European Molecular Biology Laboratory, Heidelberg, Germany) showed that the threonine-407 site is highly conserved among these species (Fig. 1B) . To examine whether Cdk5 can phosphorylate TRPV1, we used TRPV1 as substrate for Cdk5 in an in vitro kinase assay. We first checked the specificity of the TRPV1 antibody (P19) for immunoprecipitation by using a specific blocking peptide. We immunoprecipitated TRPV1 from rat DRG tissue, NIH 3T3 fibroblast cells stably transfected with TRPV1 (NIH 3T3ϩTRPV1), and cultured primary rat DRG neurons. This antibody was able to immunoprecipitate the 110-kDa TRPV1 protein from these three sources, and the immunoprecipitation was completely blocked by the specific antigen peptide used in a competitive immunoprecipitation assay (Fig. 1C) . To determined whether Cdk5 can phosphorylate endogenous TRPV1, we immunoprecipitated TRPV1 from NIH 3T3ϩTRPV1 cells and from cultured DRG neurons, and the immunoprecipitate was then used as a substrate for the Cdk5 kinase assay. The autoradiogram obtained from this kinase assay showed that Cdk5 can phosphorylate TRPV1 (Fig. 1D) . To check the specificity of TRPV1 phosphorylation by Cdk5, we immunoprecipitated Cdk5 from Cdk5 ϩ/ϩ and Cdk5 Ϫ/Ϫ mouse brains, and used them in these kinase assays. In similar experiments, the purity of Cdk5 kinase activity was confirmed by using specific substrates for Cdk5, histone H1 and NF-H peptide ( Fig. 1 E and F) . To confirm the potential site of Cdk5 phosphorylation in the TRPV1 protein, we synthesized three 7-to 9-mer peptides against predicted TRPV1 regions: peptide 1, GVETPPRLY for threonine-108; peptide 2, SSETPNRH for threonine-407; and peptide 3, VESPPHK for serine-612. These three peptides and their respective, mutated control peptides (where serine or threonine was replaced by alanine) were purified (90-95%) by HPLC and used as substrates for in vitro Cdk5 kinase assays. Quantitative analysis of this kinase assay showed that Cdk5 preferentially phosphorylates peptides 1 and 2. Peptide 2 apparently contains a much better substrate motif for Cdk5 kinase activity, which is evident from the higher level of phosphorylation in these assays (Fig. 1G) . As mentioned later, we confirmed this phosphorylation by using a specific antibody generated against the threonine-407 region (see Fig. 3D ) Inhibition of Cdk5 Activity Attenuates TRPV1-Mediated Calcium Influx in Cultured DRG Neurons. After confirming the Cdk5-mediated TRPV1 phosphorylation, we examined whether this phosphorylation had any consequences on TRPV1 function. For this purpose, we used a well established, capsaicin-induced calcium influx model in cultured DRG neurons (5, 24, 25) with or without the specific Cdk5 inhibitor roscovitine. Data from calcium influx assays in capsaicin-activated cultured DRG neurons obtained by using different concentrations of roscovitine (1.5-100 M for 2 h before capsaicin treatment) showed that inhibition of Cdk5 kinase activity attenuated capsaicin-induced calcium influx (Fig.   2 ). DRG neurons treated with the same roscovitine concentrations for 2 h and treated with capsaicin after 24 h (during this time roscovitine breaks down and is inactive) showed a normal response, suggesting a reversible effect of roscovitine on TRPV1-mediated calcium influx (Fig. 2) . Nonneuronal NIH 3T3ϩTRPV1 cells (lacking Cdk5 activity), stably transfected with rat TRPV1, also exhibited capsaicin-induced calcium influx, but this response could not be inhibited by roscovitine, which suggests a Cdk5-independent mechanism of TRPV1 activity in these cells (Fig. 2) . gesia. Now to analyze the in vivo significance of Cdk5 in primary afferent, we generated C fiber specific Cdk5-CoKO mice. The voltage-gated sodium ion channel NaV1.8 (synonymous with SNS or PN3) is specifically expressed in small-diameter sensory neurons in neonatal and adult DRG and trigeminal ganglia (26) . We generated Cdk5 knockout (Cdk5 Ϫ/Ϫ ), Cdk5-flox (Cdk5 f/f ), and SNS promoter-driven Cre transgenic mice as described (22, 27, 28) . Cdk5 f/Ϫ mice were crossed with SNS promoter-driven Cre transgenic mice to generate C-fiber neuron-specific Cdk5-CoKO mice ( Fig. 3 A and B) . Conditional deletion of Cdk5 in pain-sensing neurons of Cdk5-CoKO mice abrogated TRPV1 phosphorylation at threonine-407. This effect was confirmed by using a specific anti-phosphopeptide antibody generated against the peptide harboring the threonine-407 site ( Fig. 3 C and D) . Next we tested the Cdk5-CoKO mice for their basal thermal response by performing the modified Hargreaves test for paw withdrawal from radiant heat and a tail withdrawal test using a 50°C water bath. Cdk5-CoKO mice exhibited a delayed withdrawal response toward basal thermal stimuli in both of these tests ( Fig. 3 E and F) .
Conditional Deletion of Cdk5 in
Discussion
TRPV1 is known to play a major role in mediating moderately painful heat and hyperalgesia (8, 9) . Phosphorylation of TRPV1 by protein kinase A, protein kinase C, and calcium/calmodulin kinase II can modulate a wide range of excitabilities in response to various adverse stimuli (12) (13) (14) . Because our recent findings suggested an important function of Cdk5 in pain signaling (15, 16) , we investigated the potential of Cdk5 to directly phosphorylate proteins involved in pain signaling. Computational analysis of TRPV1 protein predicted three potential target sites for Cdk5-mediated phosphorylation, of which the conserved threonine-407 site showed highest preference. This site is located in the large amino-terminal intracellular portion of TRPV1, close to the first transmembrane domain. An overlapping phosphorylation of TRPV1 by protein kinase A, protein kinase C, or calmodulin kinase II on other intracellular serine and threonine sites is reportedly involved in TRPV1 sensitization and activation by a conformational change (29) . On the basis of these reports and our current findings, we hypothesized that Cdk5-mediated phosphorylation of TRPV1 may be important for the conformational change involved in opening the ion channels in response to ligand binding or heat activation.
We further analyzed the functional consequences of Cdk5-mediated TRPV1 phosphorylation by using a TRPV1-specific, ligand-induced calcium influx assay in cultured rat DRG neurons. There was a significant reduction in calcium influx with increasing concentrations of roscovitine from 6.25 M to 100 M. The concentrations of roscovitine used in this assay were shown to inhibit Cdk5 activity in cultured DRG neurons (30, 31) . This observation indicated that Cdk5-mediated phosphorylation of TRPV1 is important for capsaicin-mediated calcium influx through this receptor. Here, it is interesting to note that intrathecal roscovitine infusion alone produced an antinociceptive effect and attenuated formalin-induced nociceptive responses (32, 33) . These observations suggest that Cdk5-mediated TRPV1 phosphorylation is :, conserved substitution; ., semiconserved substitution. (C) TRPV1 was immunoprecipitated (IP) from DRG, NIH 3T3ϩTRPV1 cells, and DRG culture cell lysates and subjected to Western blotting using TRPV1 antibody. TRPV1 was immunoprecipitated from these lysates, as confirmed by immunodepletion experiments performed by using a TRPV1-specific peptide for the pull-down assay as shown on the right side. (D) TRPV1 protein immunoprecipitated from NIH 3T3ϩTRPV1 and DRG cultures was used as a substrate for the Cdk5 kinase assay. Cdk5 was immunoprecipitated from WT and Cdk5-knockout (KO) brain lysates by using Cdk5 antibody. Autoradiographs are shown in Upper, and corresponding Western blots are shown in Lower. Phospho-TRPV1 is clearly seen in WT but is absent in Cdk5 knockout lanes. (E and F) To confirm the specificity of C-8 immunoprecipitates from Cdk5 WT and KO lysates, histone H1 (E) and NF-H peptide (F) were used as substrates in kinase assays. Phosphorylation of the substrates was observed in WT but not KO brain samples. (E) Shown are an autoradiograph (Upper) and the corresponding Coomassie blue-stained gel (Lower). (F) Data are the mean Ϯ SEM (n ϭ 3). ** , P Ͻ 0.01, Student's t test. (G) Peptides (peptide 1, GVETPPRLY for threonine-108; peptide 2, SSETPNRH for threonine-407; and peptide 3, VESPPHK for serine-612) of the three putative Cdk5 phosphorylation sites and their corresponding nonphosphorylated mutants were synthesized. Cdk5 was immunoprecipitated from WT and Cdk5-knockout brain lysates and used as the kinase source in kinase assays. Peptide 2, corresponding to threonine-407, exhibited strong phosphorylation; peptide 1 (threonine-108) exhibited the second-strongest phosphorylation. Peptide 3 (serine-612) did not exhibit any significant phosphorylation. All data are the mean Ϯ SEM (n ϭ 3). ** , P Ͻ 0.01; NS, not significant, Student's t test. required for normal channel activity. Because the stable transfection of TRPV1 in nonneuronal (NIH 3T3) cells had no effect on TRPV1 function, it limited us to perform site-directed mutagenesis studies against Cdk5-specific regions in TRPV1.
After confirming the importance of Cdk5 on agonist-induced TRPV1 activation in cultured DRG neurons, we explored the significance of Cdk5 in primary afferent signaling in vivo. Analysis of the in vivo role of Cdk5 in pain signaling has been restricted due to the embryonic lethality of the Cdk5-knockout mice; however, it should be noted that Cdk5-knockout pups are unresponsive to noxious cutaneous pinch (34) . We recently reported an altered basal thermal response in p35-knockout (possess reduced Cdk5 activity) and transgenic p35 overexpressing (possess increased Cdk5 activity) mice (15) . Collectively, these findings indicate an important role for Cdk5 in pain signaling, but this conclusion may be influenced by the likelihood of Cdk5-and p35-knockout mice to suffer from secondary neuronal dysfunctions. To address these concerns, we generated Cdk5-CoKO mice that lacked Cdk5 expression predominantly in C-fiber neurons. We observed abrogation of TRPV1 phosphorylation at threonine-407 in DRG of these mice. Moreover, these mice showed significant hypoalgesia against basal thermal response. This phenotype of Cdk5-CoKO mice is similar to that observed in p35-and TRPV1-knockout mice, which suggests that Cdk5-mediated TRPV1 phosphorylation is important in nociceptive signaling. Thus, Cdk5-mediated TRPV1 phosphorylation is important for heat-and capsaicin-induced activation and provides insight into Cdk5-mediated pain signaling.
In conjunction with our previous reports (15, 16) , our findings in this article indicate an essential role for Cdk5 activity in pain signaling. These results provide a molecular mechanism for functional regulation of TRPV1 and bring a paradigm to develop pain analgesics targeted for Cdk5-mediated phosphorylation. Although additional work needs to be done to better understand the cause of functional consequences after Cdk5-mediated TRPV1 phosphorylation, Cdk5 appears to be an essential component of nociceptive signaling and needs more attention to develop new analgesic drug targets. We believe that the class of Cdk5-targeted analgesics described in this article will prove to be an additional therapeutic option to effectively treat many painful conditions and disorders.
Experimental Procedures
Generation of SNS-Cre-Mediated Cdk5-CoKO Mice. We generated C-fiber-specific Cdk5-CoKO mice by crossing Cdk5 f/Ϫ mice with SNS-Cre mice. To generate Cdk5-CoKO mice, the following mating strategy was performed: First, Cdk5 heterozygous (Cdk5 ϩ/Ϫ ) mice were crossed with SNS-Cre to obtain Cdk5 ϩ/Ϫ ; SNS-Cre. These mice were then crossed with Cdk5-flox homozygous (Cdk5 f/f ) mice to generate the Cdk5 f/Ϫ ; SNS-Cre (Cdk5-CoKO) mice. Cdk5 f/f and SNS-Cre littermates were used as controls. Genotypes of mice were confirmed by Southern blot analysis. For routine genotyping, the PCR method was adopted. Cdk5 f loxed alleles were detected by sense primer 5Ј-ACCGATAATCCTAGTGGGGGCACA-3Ј and antisense primer 5Ј-GATTTGAGTGGAAGGACACACGCCAG-3Ј, Cre gene expression was confirmed by sense primer 5Ј-GCACT-GATTTCGACCAGGTT-3Ј and antisense primer 5Ј-GAGT-CATCCTTAGCGCCGTA-3Ј, and Cdk5 genotyping was performed as described in ref. 35 . All animals were housed in standard cages and maintained in climate-and light-controlled rooms with free access to food and water. All experimental procedures were approved by the Animal Care and Use Committee of the National Institute of Dental and Craniofacial Research, National Institutes of Health.
Behavioral Test for Noxious Thermal Stimulation. To measure the basal sensitivity to noxious thermal stimulation, mice were subjected to a modified Hargreaves test and tail-withdrawal test as described in ref. 15 . In brief, for the Hargreaves test, the stimulus was a high-intensity focused light beam from a projector lamp bulb located below the glass floor that was aimed at the midplantar surface of the hind paw of an inactive mouse. Mice were acclimated for at least 2 h before testing, and pawwithdrawal latency was measured to the nearest 0.1 sec. For the tail-withdrawal test, mice were lightly restrained in a cloth, and the protruding distal half of the tail was then dipped into a bath of circulating water thermostatically controlled at 50°C.
Antibodies. Anti-Cdk5 (5 g) antibody C-8 (Santa Cruz Biotechnology, Santa Cruz, CA) was used for immunoprecipitation. TRPV1 goat polyclonal antibody P19 (Santa Cruz Biotechnology) was used at a 1:200 dilution for Western blotting, and 5 g was used for immunoprecipitation. TRPV1-blocking peptide P19 was purchased from Santa Cruz Biotechnology. Secondary horseradish peroxidase-conjugated antibodies were obtained from Amersham Biosciences (Piscataway, NJ) and used at 1:2000 dilution.
Generation of Anti-TRPV1-Phosphothreonine-407 Antibody. Anti-TRPV1-phosphothreonine-407 antibody (pTRPV1-Th-407) was custom-made by 21st Century Biochemicals (Marlboro, MA). In brief, rabbits were immunized with the TRPV1-phosphothreonine peptide Ac-SSE(pT)PNRHDML-Ahx-C-amide (sequence confirmed by MS Check; 21st Century Biochemicals) conjugated to keyhole limpet hemocyanin. Sera were obtained after five consecutive bleeds. To ensure the specificity of the antibody, sera obtained from immunized animals were subjected to multiple rounds of immunodepletion by passage through an affinity column of immobilized non-phosphopeptide antigen, followed by standard affinity purification using a column with the phosphopeptide antigen as ligand.
Immunoblot Analysis. Protein expression was determined by Western blot analysis as described in refs. 15 and 16. In brief, tissue homogenates were prepared in a lysis buffer consisting of 50 mM Tris⅐HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, 1 g/ml leupeptin, and 1:100 diluted phosphatase inhibitor mixtures I and II (Sigma, St. Louis, MO). Proteins were denatured, and equal amounts of proteins were electrophoresed in 4-12% bis-Tris/polyacrylamide gels (NuPAGE; Invitrogen, Carlsbad, CA) and transferred to nitrocellulose membranes with 0.45-m pores (Invitrogen). The membranes were blocked for 2 h in blocking solution [TBS containing 10% nonfat dry milk (Bio-Rad, Hercules, CA) and 0.05% Tween 20] and incubated overnight at 4°C with primary antibodies that were diluted in blocking solution. Incubation with horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG was performed at room temperature for 1 h, and immunoreactivity was detected by using enhanced chemiluminescence (Pierce, Rockford, IL). Relative optical densities of the bands were quantified by using an image analysis system with NIH Image software, version 1.62 (National Institutes of Health, Bethesda, MD).
Cdk5 Kinase Activity Assay. Tissue or cell lysates containing 500 g of protein were diluted in lysis buffer to a volume of 500 l and precleared with 50 l of protein A-agarose beads (50% slurry in lysis buffer; Santa Cruz Biotechnology) at 4°C for 2 h. Cdk5 was immunoprecipitated from precleared lysates with 5 g of anti-Cdk5 IgG during an overnight incubation at 4°C, then incubated for 3 h at 4°C with 25 l of protein A-agarose beads. Immunoprecipitates (E and F) Cdk5-CoKO and respective control mice were subjected to the Hargreaves test (E) and the tail-withdrawal test (F). In all groups, a total of 10 mice were used for each test. Cdk5-CoKO mice exhibited a delayed response against noxious thermal stimulation compared with their controls. Data are mean Ϯ SEM (n ϭ were washed twice with lysis buffer and twice with kinase buffer [20 mM Tris⅐HCl (pH 7.4)/10 mM MgCl 2 /1 mM EDTA/10 M NaF/1 M Na 2 VO 3 ] and resuspended in 30 l of water. Ten microliters of kinase assay mixture [100 mM Tris⅐HCl (pH 7.4)/50 mM MgCl 2 /5 mM EDTA/50 M NaF/5 M Na 2 VO 3 /5 mM DTT) and 10 g of histone H1 (Sigma), 0.2 M NF-H peptide (VKSPAKEKAK-SPVK), immunoprecipitated TRPV1, or TRPV1 peptides (peptide 1, GVETPPRLY; peptide 2, SSETPNRH; peptide 3, VESPPHK) were added to 30 l of the immunoprecipitates. Kinase assays were carried out at 30°C for 60 min by adding 5 Ci of [␥-
32 P]ATP (0.5 mM). In the histone H1 kinase assay, the reaction was stopped by adding 5ϫ SDS sample buffer and boiling for 5 min, and the peptide assay was stopped by adding a similar volume of 10% trichloroacetic acid to precipitate proteins. To detect TRPV1 phosphorylation, 20-l aliquots were electrophoresed on a 10% polyacrylamide gel, which was stained with Coomassie blue, destained, dried, and exposed overnight to a phosphoscreen. The phosphoscreen was scanned on a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA), and the bands were quantified with ImageQuant software (Molecular Dynamics). For the peptide kinase assay, 20-l aliquots of trichloroacetic acid supernatant were transferred onto P81 phosphocellulose squares (spotted in duplicates), air-dried, and washed five times for 15 min each in 75 mM phosphoric acid and once in 95% ethanol. After air drying, squares were transferred to vials containing Bio-Safe II scintillation fluid (Research Products International, Mount Prospect, IL) for counting in a Beckman Coulter (Fullerton, CA) scintillation counter (model no. SL 3801).
DRG Cultures and 45 Ca 2؉ Uptake Assay. Pregnant female rats were killed, and embryos were removed by cesarean at embryonic day 15 for primary DRG cultures as described (5, 15) . Briefly, cells were dissociated with 0.125% trypsin/EDTA in Ca 2ϩ /Mg 2ϩ -free Hanks' balanced salt solution for 30 min at 37°C, triturated, and plated in MEM [containing 5% horse serum and N3 supplement (36) ] with 100 ng/ml nerve growth factor. Cells were seeded onto collagencoated 96-well plates, and the next day, fresh medium containing mitotic inhibitors (uridine and 5-fluoro-2Ј-deoxyuridine) was added. DRG were assayed for 45 Ca 2ϩ uptake assay on 4-6 days after plating. NIH 3T3 cells stably expressing TRPV1 (5) were seeded at a density of 5 ϫ 10 4 cells per well the day before assaying.
All cells were grown in a humidified 5% CO 2 chamber at 35°C. Cells were treated with roscovitine (Biomol, Plymouth Meeting, PA) diluted into complete growth medium. Roscovitine was serially diluted from 100 M to 1.25 M in a 96-well plate, prewarmed, and then directly added to cells. Cells were incubated for 2 h at 37°C, after which they were assayed, or, in the case of recovery experiments, the medium was changed, and the cells were assayed 24 h later. The calcium uptake assays were performed on an automated robotic liquid-handling system (Biomek FX; Beckman Coulter). The assay buffer contained 1ϫ Hanks' balanced salt solution, 25 mM Tris⅐HCl (pH 7.5), 1.6 mM MgCl 2 , 20 M CaCl 2 , 1 mM ascorbic acid, and BSA. Plates containing cells were removed from the incubator and allowed to equilibrate to room temperature for 5 min. Cells were washed three times with assay buffer to remove medium. After the wash, cells were incubated with 2 M capsaicin (Fluka, St. Louis, MO) and 0.5 Ci of 45 Ca 2ϩ per well in assay buffer for 10 min. The cells were washed five times with assay buffer, then lysed with radio-immunoprecipitation assay buffer (50 mM Tris⅐HCl (pH 7.5)/150 mM NaCl/1% Triton X-100/0.5% deoxycholate/0.1% SDS/5 mM EDTA) for 30 min. Aliquots of the cell extracts were transferred to a 96-well plate containing Microscint 40 scintillation fluid (PerkinElmer Life Sciences, Wellesley, MA), and the intracellular 45 Ca 2ϩ was counted by using a Packard TopCount NXT scintillation counter (PerkinElmer Life Sciences).
Statistical Analysis. All experiments were performed a minimum of three times. Statistical evaluation was done with Graph Pad Prism version 4.0 software (Graph Pad Software, San Diego, CA). Significant differences between experiments were assessed by univariate ANOVA (more than two groups) or unpaired Student's t test (two groups). ANOVA was followed by Student's t tests with a Bonferroni ␣-correction for multiple comparisons, where ␣ was set at 0.05.
